Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia

Markéta Žaliová(Novartis (Switzerland)), Jan Trka(Charles University), Jan Starý(Charles University), Gunnar Cario, Jean‐Pierre Bourquin(University Children's Hospital Zurich), Eliška Potůčková(Charles University), Lucie Winkowska(Charles University), Lucie Šrámková(University Hospital in Motol), Júlia Starková(Charles University), Jan Zuna(Charles University), Cornelia Eckert(Humboldt-Universität zu Berlin), J Lukes(Charles University), Iveta Janotová(University Hospital in Motol), Beat Bornhäuser(University Children's Hospital Zurich), Martin Zimmermann(Stichting Kinderoncologie Nederland), Martin Stanulla(Leibniz University Hannover)
Haematologica
June 4, 2020
10.3324/haematol.2020.249094
Cited by 21

Related Papers

Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
|Leukemia|2009|338
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
|Journal of Clinical Investigation|2010|311
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
|Journal of Clinical Oncology|2018|304